JPWO2021113541A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021113541A5 JPWO2021113541A5 JP2022534221A JP2022534221A JPWO2021113541A5 JP WO2021113541 A5 JPWO2021113541 A5 JP WO2021113541A5 JP 2022534221 A JP2022534221 A JP 2022534221A JP 2022534221 A JP2022534221 A JP 2022534221A JP WO2021113541 A5 JPWO2021113541 A5 JP WO2021113541A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aso
- composition according
- aspects
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025264280A JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945048P | 2019-12-06 | 2019-12-06 | |
| US62/945,048 | 2019-12-06 | ||
| US202062993971P | 2020-03-24 | 2020-03-24 | |
| US62/993,971 | 2020-03-24 | ||
| PCT/US2020/063157 WO2021113541A1 (en) | 2019-12-06 | 2020-12-03 | Antisense oligomers for treatment of conditions and diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025264280A Division JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504195A JP2023504195A (ja) | 2023-02-01 |
| JP2023504195A5 JP2023504195A5 (https=) | 2023-12-07 |
| JPWO2021113541A5 true JPWO2021113541A5 (https=) | 2023-12-07 |
Family
ID=76222665
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534221A Pending JP2023504195A (ja) | 2019-12-06 | 2020-12-03 | 状態および疾患の処置のためのアンチセンスオリゴマー |
| JP2025264280A Pending JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025264280A Pending JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230116704A1 (https=) |
| EP (1) | EP4069256A4 (https=) |
| JP (2) | JP2023504195A (https=) |
| KR (1) | KR20220113743A (https=) |
| CN (1) | CN115087452A (https=) |
| AU (1) | AU2020395835A1 (https=) |
| BR (1) | BR112022010882A2 (https=) |
| CA (1) | CA3159162A1 (https=) |
| IL (1) | IL293531A (https=) |
| MX (1) | MX2022006858A (https=) |
| WO (1) | WO2021113541A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| WO2021174036A1 (en) * | 2020-02-28 | 2021-09-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating scn1a expression |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| EP4392562A4 (en) * | 2021-08-27 | 2025-09-24 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION |
| EP4562020A2 (en) * | 2022-07-29 | 2025-06-04 | Stoke Therapeutics, Inc. | Compounds for treatment of conditions and diseases |
| JP2025526712A (ja) * | 2022-08-11 | 2025-08-15 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| EP4665407A2 (en) * | 2023-02-14 | 2025-12-24 | Stoke Therapeutics, Inc. | Antisense oligomer formulations |
| MX2025013084A (es) * | 2023-05-03 | 2026-02-03 | Stoke Therapeutics Inc | Compuestos y métodos para tratar sujetos humanos |
| WO2026036032A1 (en) * | 2024-08-09 | 2026-02-12 | Amylyx Pharmaceuticals, Inc. | Formulations containing antisense oligonucleotides targeting calpain-2 |
| WO2026052819A1 (en) * | 2024-09-06 | 2026-03-12 | Ospedale San Raffaele S.R.L. | Gene therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503756B1 (en) * | 2000-09-22 | 2003-01-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of syntaxin 4 interacting protein expression |
| WO2011163499A2 (en) * | 2010-06-23 | 2011-12-29 | Opko Curna, Llc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
| EP3933041B1 (en) * | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
| SG11202001590RA (en) * | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| GB2610100B (en) * | 2017-10-23 | 2023-08-16 | Stoke Therapeutics Inc | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases |
| WO2019224864A1 (ja) * | 2018-05-21 | 2019-11-28 | 国立研究開発法人理化学研究所 | Ｓｃｎ１ａ遺伝子の発現増強法とそれによるドラベ症候群の治療法 |
| KR20210134003A (ko) * | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
-
2020
- 2020-12-03 BR BR112022010882A patent/BR112022010882A2/pt unknown
- 2020-12-03 JP JP2022534221A patent/JP2023504195A/ja active Pending
- 2020-12-03 WO PCT/US2020/063157 patent/WO2021113541A1/en not_active Ceased
- 2020-12-03 CN CN202080095947.9A patent/CN115087452A/zh active Pending
- 2020-12-03 AU AU2020395835A patent/AU2020395835A1/en active Pending
- 2020-12-03 EP EP20897381.8A patent/EP4069256A4/en active Pending
- 2020-12-03 CA CA3159162A patent/CA3159162A1/en active Pending
- 2020-12-03 KR KR1020227023111A patent/KR20220113743A/ko active Pending
- 2020-12-03 MX MX2022006858A patent/MX2022006858A/es unknown
- 2020-12-03 IL IL293531A patent/IL293531A/en unknown
-
2022
- 2022-06-03 US US17/832,182 patent/US20230116704A1/en active Pending
-
2025
- 2025-12-18 JP JP2025264280A patent/JP2026048892A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI702045B (zh) | 治療甲狀腺素運載蛋白（ｔｔｒ）調節之澱粉樣變性的方法 | |
| US9725716B2 (en) | Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease | |
| US8980853B2 (en) | Compositions and methods for modulation of SMN2 splicing in a subject | |
| JPWO2021113541A5 (https=) | ||
| Smith et al. | Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime | |
| JP2011502118A (ja) | 筋障害を相殺するための手段と方法 | |
| US20160184456A1 (en) | Anticancer combinations | |
| EP4373935A1 (en) | Unc13a antisense oligonucleotides | |
| AU2007207606A1 (en) | Central administration of stable formulations of therapeutic agents for CNS conditions | |
| CN102753188A (zh) | 治疗脑瘤的方法 | |
| CN120112639A (zh) | Angptl3相关疾病和病症的治疗方法 | |
| JP2022520885A (ja) | 神経変性疾患を処置するための組成物および方法 | |
| US20240417725A1 (en) | Oligonucleotides for targeting complement c5 | |
| MX2007006591A (es) | Composici??n terap??utica de oligonucle??tidos de antisentido para el tratamiento de la enfermedad intestinal inflamatoria. | |
| US20230348586A1 (en) | Therapeutic agents and uses thereof | |
| WO2026085179A1 (en) | Antisense cancer therapeutics with alkylating agents | |
| HK40088348A (en) | Methods of treating transthyretin (ttr) mediated amyloidosis | |
| WO2025052391A1 (en) | Antisense oligonucleotides targeting the cftr 3849+10 kilobase (kb) c->t splicing mutation | |
| CN116322781A (zh) | Pcsk9抑制剂及使用其的治疗方法 | |
| KR20260055532A (ko) | 병태 및 질환 치료 방법 | |
| CN116635040A (zh) | 用非妥西兰治疗血友病 | |
| JPH0826994A (ja) | 脳血管攣縮治療剤 | |
| WO2007013845A1 (en) | Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution | |
| Rendina et al. | SELECTIVE BILIRUBIN APHERESIS IN THE MANAGEMENT OF PATIENTS WITH ACUTE ON CHRONIC LIVER DECOMPENSATION AND PATIENTS WITH LIVER TRANSPLANTATION | |
| De Cento et al. | SEDATION FOR ENDOSCOPY IN PATIENTS WITH END-STAGE LIVER DISEASE: RESULTS OF A PROSPECTIVE CONTROLLED STUDY |